Q32 Bio (QTTB) Free Cash Flow Growth (1y) (2018 - 2026)
Q32 Bio (QTTB) Free Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Q32 Bio | 215.94 Mn | 165.19 Mn | - | 50.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.48% |
| Dec 31, 2025 | 37.88% |
| Sep 30, 2025 | 82.06% |
| Jun 30, 2025 | 51.03% |
| Mar 31, 2025 | 12.66% |
| Dec 31, 2024 | -9.02% |
| Sep 30, 2024 | -226.47% |
| Jun 30, 2024 | -94.08% |
| Mar 31, 2024 | -17.58% |
| Dec 31, 2023 | 60.62% |
| Sep 30, 2023 | 163.76% |
| Jun 30, 2023 | 64.46% |
| Mar 31, 2023 | 59.43% |
| Dec 31, 2022 | 17.03% |
| Sep 30, 2022 | -4.61% |
| Jun 30, 2022 | -26.58% |
| Mar 31, 2022 | -1.83% |
| Dec 31, 2021 | -196.89% |
| Sep 30, 2021 | 19.28% |
| Jun 30, 2021 | 2.54% |